BioCentury
ARTICLE | Clinical News

MOR209/ES414: Phase I started

March 23, 2015 7:00 AM UTC

Emergent BioSolutions Inc. (NYSE:EBS), Rockville, Md. MorphoSys AG (Xetra:MOR; Pink:MPSYF), Martinsried, Germany Product: MOR209/ES414 (formerly ES414) Business: Cancer Molecular target: Prostate-s...